Alex Spira, M.D.
@AlexSpiraMDPhD
Followers
1K
Following
1K
Media
21
Statuses
991
Alex Spira, M.D., PhD, F.A.C.P. Medical Oncologist/Director VCS Research Institute & Phase I Trial Program. #VCSpecialists Virginia Cancer Specialists
Fairfax, VA
Joined October 2016
RT @HHorinouchi: š#ASCO25 REVIEWš.āļø#LCSM Rapid Oral, Mets.š„LOXO-RAS-20001: Olomorasib + immunotherapy in first-line Tx of pts with KRAS G1ā¦.
0
5
0
RT @diegoadiazg: šØ @ASCO Olomorasib + pembrolizumab in 1L advanced KRAS G12C NSCLC shows encouraging efficacy across all PD-L1 levels.š¹ ORRā¦.
0
4
0
RT @OncoAlert: Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Resulā¦.
0
18
0
RT @donnashort: These posters were next to each other. Excitement from ā¦@AlexSpiraMDPhDā© bubbling over ā¦@ASCOā© #GI25 #revolutionmed #kentbaā¦.
0
2
0
RT @TargetedOnc: WATCH: @AlexSpiraMDPhD of @VCSpecialists discusses the clinical implications of ctDNA for treatment decisions and monitoriā¦.
targetedonc.com
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in patients with KRAS G12D pancreatic ductal adenocarcinoma treated with...
0
6
0
RT @OncLive: Thank you to @AlexSpiraMDPhD, of @VCSpecialists, who spoke with us at #GI25 about findings from a phase 1 study of RMC-9805 inā¦.
0
2
0
RT @OncLive: RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12DāMutated PDAC @AlexSpiraMDPhD @ASCO #GI25 #panā¦.
onclive.com
Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12Dāmutated PDAC.
0
1
0
RT @StephenVLiu: CHRYSALIS-2 Cohort A: amivantamab + lazertinib in #EGFR NSCLC after osimertinib and chemotherapy @JTOonline (n=162). BICRā¦.
0
35
0
RT @NEJM: In the MARIPOSA trial, researchers assessed the efficacy and safety of amivantamabālazertinib, as compared with osimertinib, as fā¦.
0
9
0
RT @CancerNetwrk: An ORR of 74% (95% CI, 48.8%-90.9%) among 19 evaluable patients was observed, with anti-tumor activity occurring across aā¦.
cancernetwork.com
Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.
0
2
0
RT @JulieBrahmer: Well #WCLC2024 is a wrap! @PatelOncology @NarjustFlorezMD and their cochairs as well as the IASLC staff - outstanding joā¦.
0
7
0
RT @OncNewsCentral: Study MARIPOSA: FDA approves amivantamab-vmjw + lazertinib as first-line for EGFR+ NSCLC. Superior PFS over osimertinibā¦.
oncologynewscentral.com
The FDA approved amivantamab-vmjw plus lazertinib in the first-line setting for NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
0
1
0
RT @oncodaily: šØNew Paper Alert!šØ Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Resultsā¦.
0
6
0
RT @Latinamd: I was invited to speak on mgmt of AEs for new #lungcancer EGFR therapies and learned so much more from this great panel of eā¦.
0
4
0
RT @Aiims1742: A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial intā¦.
nature.com
Nature Medicine - In an interim analysis of a phase 1/2 trial, a heterologous prime boost vaccine comprised of a chimpanzee adenovirus and self-amplifying mRNA that encodes neoantigens derived from...
0
26
0
RT @TargetedOnc: The MARIPOSA trial of amivantamab + lazertinib vs standard-of-care osimertinib for the treatment of EGFR-mutated #NSCLC haā¦.
targetedonc.com
According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung...
0
2
0
RT @letswinpc: A2.1 Because pancreatic cancer is very difficult to treat, patients may want to consider participating in a clinical trial.ā¦.
0
3
0
RT @OncLive: Dipiti Patel Donnelly, MD, of @VCSpecialists joined us to discuss how clinicians can manage high-risk hematologic malignanciesā¦.
0
3
0
RT @TargetedOnc: Experts discuss results from MARIPOSA-2 and the role of amivantamab + lazertinib + chemotherapy in patients with advancedā¦.
targetedonc.com
Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.
0
3
0